FiercePharma

FDA Approves Deltoid Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...
Healio

FDA approves new injection site for Abilify Maintena to treat schizophrenia

Please provide your email address to receive an email when new articles are posted on . Otsuka Pharmaceutical, Inc. and Lundbeck recently announced the FDA expanded the label of Abilify Maintena for ...
EurekAlert!

US FDA approves ABILIFY for adolescent patients with schizophrenia

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...
FierceBiotech

PRESS RELEASE: FDA Approves Otsuka Pharmaceutical and Bristol-Myers Squibb's ABILIFY for Adolescent Patients With Schizophrenia

TOKYO and PRINCETON, N.J., Nov. 6 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY - News) announced today that the U.S. Food and Drug Administration (FDA) approved the ...
Medscape

Once-Monthly Aripiprazole Effective in Bipolar Disorder

A long-acting, injectable form of the antipsychotic drug aripiprazole (Abilify, Otsuka) given once a month provides a safe and effective means of maintenance therapy for the treatment of bipolar I ...
FierceBiotech

FDA Approves Once-Monthly ABILIFY MAINTENA™ (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...